Table 3.
Summary of tumor board recommendations.
| Recommendations | Tumor Board presentations, N (%) |
|---|---|
| Surgery | 458 (22) |
| Chemotherapy | 260 (13) |
| Radiation therapy | 129 (6) |
| Endocrine treatment | 39 (2) |
| Eligibility for clinical trial(s)a | 270 (13) |
| Cancer Risk & Prevention Program | 56 (3) |
| Further work up | 446 (22) |
| Imaging | 150 (7) |
| Biopsy | 63 (3) |
| Dilatation and curettage | 35 (2) |
| Tumor markers | 53 (3) |
| Specialty consultations | 76 (4) |
| Otherb | 69 (3) |
| No treatment | 380 (19) |
| Total | 2038 |
a
N represents the sum of tumor board letters that stated patient eligibility for clinical trial, regardless of the number of trials recommended.
b
Other: exam under anesthesia (12), unspecified (10), tumor board re-presentation (9), pap smear (7), colposcopy (6), cystoscopy (5), hysteroscopy (4), proctoscopy (3), serial beta hcg (2), HPV testing (2), HPV vaccine (2), pain clinic (2), urinalysis (1), urine cytology (1), laparoscopy (1), drainage (1), and laser ablation (1).